Oncolytics Biotech Announces Positive Clinical Trial Results for...
Oncolytics Biotech Inc. , currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced positive clinical trial results for pelareorep in the treatment of patients with KRAS mutant metastatic colorectal cancer. Patients receiving treatment with the recommended phase 2 dose of pelareorep in combination with FOLFIRI/B had progression free survival of 65.6 weeks and an overall survival of 107.5 weeks, which exceeded expectations when compared to historical data.
from Biotech News
0 Comments